Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1989 1
1991 1
1992 2
1996 1
1997 1
1998 1
2000 2
2001 4
2002 2
2003 2
2005 2
2006 3
2007 3
2008 3
2011 1
2012 6
2013 7
2014 4
2015 5
2016 3
2017 3
2018 1
2019 2
2020 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.
Vissing CR, Axelsson Raja A, Day SM, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Bundgaard H, Orav EJ, Ho CY; Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators. Vissing CR, et al. Among authors: murphy am. JAMA Cardiol. 2023 Nov 1;8(11):1083-1088. doi: 10.1001/jamacardio.2023.2808. JAMA Cardiol. 2023. PMID: 37672268 Clinical Trial.
Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression. OBJECTIVE: To explore the potential for valsartan to modify disease development, and to characterize short-term phenotyp …
Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease …
Transforming Growth Factor-β Analysis of the VANISH Trial Cohort.
Kim Y, Mastali M, Van Eyk JE, Orav EJ, Vissing CR, Day SM, Axelsson Raja A, Russell MW, Zahka K, Lever HM, Pereira AC, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Soslow JH, Becker JR, Seidman CE, Ho CY; VANISH Investigators. Kim Y, et al. Among authors: murphy am. Circ Heart Fail. 2023 Apr;16(4):e010314. doi: 10.1161/CIRCHEARTFAILURE.122.010314. Epub 2023 Mar 31. Circ Heart Fail. 2023. PMID: 36999957 Free PMC article. No abstract available.
Alteration in tyrosine phosphorylation of cardiac proteome and EGFR pathway contribute to hypertrophic cardiomyopathy.
Xu M, Bermea KC, Ayati M, Kim HB, Yang X, Medina A, Fu Z, Heravi A, Zhang X, Na CH, Everett AD, Gabrielson K, Foster DB, Paolocci N, Murphy AM, Ramirez-Correa GA. Xu M, et al. Among authors: murphy am. Commun Biol. 2022 Nov 15;5(1):1251. doi: 10.1038/s42003-022-04021-4. Commun Biol. 2022. PMID: 36380187 Free PMC article.
Alterations of serine/threonine phosphorylation of the cardiac proteome are a hallmark of heart failure. However, the contribution of tyrosine phosphorylation (pTyr) to the pathogenesis of cardiac hypertrophy remains unclear. ...
Alterations of serine/threonine phosphorylation of the cardiac proteome are a hallmark of heart failure. However, the contribution of …
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators; Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Ho CY, et al. Among authors: murphy am. Nat Med. 2021 Oct;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4. Epub 2021 Sep 23. Nat Med. 2021. PMID: 34556856 Free PMC article. Clinical Trial.
Hypertrophic cardiomyopathy (HCM) is often caused by pathogenic variants in sarcomeric genes and characterized by left ventricular (LV) hypertrophy, myocardial fibrosis and increased risk of heart failure and arrhythmias. There are no existing therapies to modify diseas …
Hypertrophic cardiomyopathy (HCM) is often caused by pathogenic variants in sarcomeric genes and characterized by left ventricular (LV) hype …
Genetic Dilated Cardiomyopathy Due to TTN Variants Without Known Familial Disease.
Brown EE, Murray B, Vaishnav J, Tampakakis E, Barouch LA, James C, Murphy AM, Judge DP. Brown EE, et al. Among authors: murphy am. Circ Genom Precis Med. 2020 Dec;13(6):e003082. doi: 10.1161/CIRCGEN.120.003082. Epub 2020 Nov 15. Circ Genom Precis Med. 2020. PMID: 33190517 Free PMC article. No abstract available.
Baseline Characteristics of the VANISH Cohort.
Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY. Axelsson Raja A, et al. Among authors: murphy am. Circ Heart Fail. 2019 Dec;12(12):e006231. doi: 10.1161/CIRCHEARTFAILURE.119.006231. Epub 2019 Dec 9. Circ Heart Fail. 2019. PMID: 31813281 Free PMC article. Clinical Trial.
BACKGROUND: The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsartan can modify disease …
BACKGROUND: The VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted y …
Genetic aetiologies should be considered in paediatric cases of acute heart failure presumed to be myocarditis.
Brown EE, McMilllan KN, Halushka MK, Ravekes WJ, Knight M, Crosson JE, Judge DP, Murphy AM. Brown EE, et al. Among authors: murphy am. Cardiol Young. 2019 Jul;29(7):917-921. doi: 10.1017/S1047951119001124. Epub 2019 Jun 14. Cardiol Young. 2019. PMID: 31198128
There are a variety of causes of acute heart failure in children including myocarditis, genetic/metabolic conditions, and congenital heart defects. In cases with a structurally normal heart and a negative personal and family history, myocarditis is often pres …
There are a variety of causes of acute heart failure in children including myocarditis, genetic/metabolic conditions, and congenital …
Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.
Axelsson Raja A, Farhad H, Valente AM, Couce JP, Jefferies JL, Bundgaard H, Zahka K, Lever H, Murphy AM, Ashley E, Day SM, Sherrid MV, Shi L, Bluemke DA, Canter CE, Colan SD, Ho CY. Axelsson Raja A, et al. Among authors: murphy am. Circulation. 2018 Aug 21;138(8):782-792. doi: 10.1161/CIRCULATIONAHA.117.032966. Circulation. 2018. PMID: 29622585 Free PMC article.
In the subset of patients with serial imaging, statistically significant increases in LGE, LV mass, and left atrial size were detected over 2.5 years, indicating disease progression over time. Further prospective studies are required to confirm these findings and to better …
In the subset of patients with serial imaging, statistically significant increases in LGE, LV mass, and left atrial size were detected over …
Heart Failure-Related Hyperphosphorylation in the Cardiac Troponin I C Terminus Has Divergent Effects on Cardiac Function In Vivo.
Li Y, Zhu G, Paolocci N, Zhang P, Takahashi C, Okumus N, Heravi A, Keceli G, Ramirez-Correa G, Kass DA, Murphy AM. Li Y, et al. Among authors: murphy am. Circ Heart Fail. 2017 Sep;10(9):e003850. doi: 10.1161/CIRCHEARTFAILURE.117.003850. Circ Heart Fail. 2017. PMID: 28899987 Free PMC article.
CONCLUSIONS: Hyperphosphorylation of this serine in cTnI C terminus impacts heart function by depressing diastolic function at baseline and limiting systolic reserve under physiological stresses. However, paradoxically, it preserves heart function after ischemia/rep …
CONCLUSIONS: Hyperphosphorylation of this serine in cTnI C terminus impacts heart function by depressing diastolic function at baseli …
The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association.
Musunuru K, Ingelsson E, Fornage M, Liu P, Murphy AM, Newby LK, Newton-Cheh C, Perez MV, Voora D, Woo D; American Heart Association Committee on Molecular Determinants of Cardiovascular Health of the Council on Functional Genomics and Translational Biology and Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Stroke Council. Musunuru K, et al. Among authors: murphy am. Circ Cardiovasc Genet. 2017 Aug;10(4):e000037. doi: 10.1161/HCG.0000000000000037. Circ Cardiovasc Genet. 2017. PMID: 28760750 Review.
There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications …
There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. …
62 results